Prognostic significance of CD3+ tumor-infiltrating lymphocytes in patients with endometrial carcinoma
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
25275055
PII: 34/10/5555
Knihovny.cz E-resources
- Keywords
- Biomarkers, endometrial carcinoma, tumor-associated macrophages, tumor-infiltrating lymphocytes,
- MeSH
- CD3 Complex metabolism MeSH
- Leukocytes immunology pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Endometrial Neoplasms immunology mortality pathology surgery MeSH
- Cell Count MeSH
- Prognosis MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Neoplasm Grading MeSH
- Lymphocytes, Tumor-Infiltrating immunology metabolism MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- CD3 Complex MeSH
AIM: The aim of the present study was to investigate tumor-infiltrating leukocytes in patients with endometrial carcinoma. PATIENTS AND METHODS: Cluster of differentiation (CD)3(+), CD8(+) and C20(+) tumor-infiltrating lymphocytes (TILs) and CD68(+) tumor-associated macrophages (TAMs) were evaluated retrospectively by immunohistochemistry in tumor specimen from 124 patients with endometrial carcinoma. RESULTS: A significant decrease of CD3(+) TILs and an increase of CD68(+) TAM count was associated with higher tumor stage. In patients with early-stage, high-risk tumors, low intraepithelial CD3(+) TIL counts were associated with significantly inferior survival. In multivariate analysis of patients with early-stage tumors, intraepithelial CD3(+) TIL counts were an independent predictor of survival. CONCLUSION: In patients with endometrial carcinoma a decrease of intraepithelial CD3(+) TIL counts is associated with advanced stage and high risk group. Intraepithelial CD3(+) TIL counts are an independent predictor of survival in patients with early tumors.
Trends in peritoneal surface malignancies: evidence from a Czech nationwide population-based study
Neopterin as a biomarker of immune response in cancer patients
